Target intelligence / Profile preview

RNA, U6 small nuclear 696, pseudogene (RNU6-696P)

Target
RNU6-696P
Molecular classification
Pseudogene, Non-coding RNA pseudogene, Small nuclear RNA (snRNA) pseudogene
01

Overview

RNU6-696P is a pseudogene derived from the U6 small nuclear RNA gene family. U6 snRNA is an essential and highly conserved non-coding RNA in eukaryotes, serving as a crucial catalytic component of the spliceosome responsible for splicing pre-mRNA. Vertebrate genomes often contain many U6-derived pseudogenes; these are DNA sequences with high similarity to functional U6 snRNA genes, but lack the regulatory or coding capacity to generate a functional snRNA molecule[3][1]. RNU6-696P does not produce a functional RNA or protein, shows no direct biological activity, and is not classified as a therapeutic target. Some studies report altered expression of RNU6-696P in diseases such as nasopharyngeal carcinoma, but its role appears to be limited to that of a marker rather than a functional contributor to cellular processes[2]. Key Points: - Not a protein, receptor, enzyme, or transporter. - Lacks direct function; derivative of a gene crucial in pre-mRNA splicing (the functional U6 snRNA, which is not the same as the pseudogene). - Not a therapeutic target; not druggable; no known drugs interact with it. - Downregulation may be detected in certain cancers but not as a mechanistic driver[2]. - Should not be used as a synonym for functional U6 snRNA or its complex. Summary: RNU6-696P is a pseudogene of U6 small nuclear RNA, not a functional molecule, protein, or actionable drug target. It is most relevant as an expression marker in specific research settings and should not be confused with canonical U6 snRNA, a molecule essential for spliceosomal function[2][3][1].

Other names
RNU6-696P
02

Biological functions

No direct biological function (as a pseudogene)
03

Disease associations

Some differential expression reported in cancer (e.g., nasopharyngeal carcinoma), but not as an active disease driver—rather as a marker of genomic or expression changes in disease context
04

Biomarkers

Mentioned as significantly downregulated in nasopharyngeal carcinoma, making it a potential expression biomarker for research, but not widely validated

Beyond the preview

Go deeper on RNA, U6 small nuclear 696, pseudogene (RNU6-696P).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RNA, U6 small nuclear 696, pseudogene (RNU6-696P).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call